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1 Introduction 
1.1 Inflammation 
1.1.1 Innate immunity 
 
The innate immune system forms the early barriers in the defense against invading 
microorganisms. Our knowledge of the cells, cascade systems and structures that forms 
the innate immune system are still expanding, but traditionally cells like granulocytes, 
mast cells, macrophages/monocytes, natural killer cells and dendrittic cells, as well as 
the complement protein cascade system are often mentioned as innate (1, 2). Innate 
immunity depends upon germline-encoded receptors and does not exhibit features like 
clone selection and clone expansion which are hallmarks of the adaptive immune 
system. The system relies on detection of conserved or common features of the 
invaders. These structures are often refered to as pathogen-associated molecular patterns 
(PAMPs) and the innate immune recognition proteins are accordingly called pattern-
recognition receptors (PRR) (3-6). An important set of PRRs are the Toll-like receptors 
discussed later. The recognition of these “patterns” makes the system fast acting; the 
respons is immediate while adaptive immune responses take days. Innate immune 
receptors do not only detected foreign structures (non-self) but also damaged tissue of 
the host (damaged self). A proposed name for structures arising from damaged tissues is 
alarmins (7). According to this, the system recognize “danger” whether it is foreign 
(PAMPs) or damaged self (alarmins) and the structures recognized could collectively be 
called danger-associated molecular patterns (DAMPs) (7, 8). The term DAMP, is often 
refered to as damaged-associated molecular patterns, and was originally postulated as an 
endogenous counterpart to PAMPs arising from damaged self (9-11). In this Thesis, 
however, I will use the term DAMP as danger-associated molecular patterns which 
include both exogenous PAMPs and endogenous damaged self (alarmins). Both PAMPs 
and damaged self (alarmins) are operative in innate immune recognition and research 
over the past 10 - 15 years suggest they both can be applied as important in initiating 
innate immune responses (12, 13).  
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The “phenotype” of most induced responses resulting from innate immune recognition, 
whether the recognition is endogenous (damaged self) or exogenous (microorganisms) 
of origin, is inflammation. The main function of inflammation is to resolve the infection 
or repair the damage and subsequently return to a state of homeostasis (14). 
Macrophages/monocytes and granulocytes and other cells secrete a range of 
inflammatory mediators collectively called cytokines. Cytokines mediate their effect 
locally in the tissues as well as systemically. They can act in autokrine, paracrine or 
endocrine manner, inducing their effects on the cells who released the cytokine, on 
adjacent cells or on distant cells respectively (2). The cytokines induce a range of 
effects like chemotaxis, upregulation of receptors on cells, trigger blood clotting, and 
capillary leak (15-17). Effects of the cytokines along with effects of a range of other 
mediators like lipid-metabolites and reactive-oxygen species “create” the state of 
inflammation (14).  
1.1.2 Toll-like receptors 
 
The german word for “great” is “Toll”. And indeed, the detection of the Toll-like 
receptors (TLRs) has been a major advance and “great” for understanding of innate 
immune recognition and activation. The precence of receptors with functions like the 
TLRs was predicted years before they were discovered (3). In particular, the search for a 
transmembrane receptor for lipopolysaccharide (LPS) of Gram-negative bacteria was 
intense. The membrane-bound CD14 was found to bind LPS and mediate LPS-effects 
(18, 19), but as the molecule was glycosylphosphatidylinositol (GPI)-anchored and not 
transmembrane it was an enigma how the signalling to the inside of the cell could occur 
(20). Toll was first discovered in the fruit-fly Drosophila as a regulator of dorsal-ventral 
pattern formation in the fly embryo (21, 22). Later it was found that Toll was 
responsible for the anti-fungal response in adult Drosophila, and thereby was an 
important part of the immune defence in the fly (23). Soon Toll was also found in 
humans (24), and after that TLR4 was discovered to be the long-sought transmembrane 
LPS-receptor (25). The TLR familiy now consist of 13 members in mice and humans 
together (26). All of the TLRs with known function recognize, as predicted, conserved 
molecules or patterns like membrane-constituents, DNA or RNA of a variety of 
microbes (27). Interestingly, recent findings indicate that TLRs not only recognize 
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exogenous microbial ligands (PAMPs) but various endogenous ligands (alarmins) as 
well (27, 28). Endogenous ligand recognition is most extensively studied for TLR4, 
among others heparan sulphate shedded from damaged endothelium (29), heat-shock 
proteins and fibrinogen are recognized by the receptor (30, 31). All the TLRs’ ligands, 
wether they are exogenous or endogenous, named either PAMPs or alarmins, signals 
danger to the host (27). The TLRs with theire wide range of exogenous and endogenous 
ligands are thereby one of the most important PRRs of the innate immune system and 
equally important in sterile induced danger, like ischemia-reperfusion (I/R) injury (32, 
33), as in danger induced by microbes. 
1.1.3 Toll-like receptors, lipopolysaccharide and Gram-negative bacteria 
 
LPS is an important constituent of the outer membrane of Gram-negative bacteria, it 
mediates many of the proinflammatory effects of these pathogens and is thereby an 
important PAMP. After the detection of the TLRs, the TLR4 was shortly after 
recognized as the transmembrane LPS receptor in mice as mentioned earlier (25). 
However, other TLRs, in particular TLR2 was found to bind LPS and induce LPS 
signalling as well. Indeed, TLR2 was thought to be the human receptor for LPS (34, 
35). Further evidence, however, confirmed that the TLR4 was the LPS receptor in mice 
(36), and in humans TLR2 signalling by LPS was shown to be due to impurities of the 
LPS preparations used (37, 38). TLR4 is now established as the sole LPS receptor (39). 
TLR4 by itself is not enough to bind LPS and trigger appropriate downstream 
intracellular signalling. CD14 was detected earlier than the TLRs and found to bind the 
complex of LPS bound to the plasma LPS-binding protein (LBP) (18, 40). With the 
detection of TLR4 as the transmembrane LPS signal conduit, CD14 was recognized as 
an important and necessary co-receptor with high specificity for LPS (41). Additionally, 
a soluble protein called myeloid-derived factor-2 (MD-2) which associate with the 
extracellular domain of TLR4, was detected and shown to be important in LPS induced 
TLR4 signalling (42). When bound to CD14, LPS is transferred to the TLR4/MD-2 
complex (43) and once LPS is bound to TLR4, the Toll-receptors oligomerize and 
trigger the downstream intracellular cascade (27, 44). At least two intracellular 
signalling pathways downstream of TLR4 exist, the MyD88-dependent and –
independent pathways (45), and the signalling cascade culminates on the nuclear 
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transcription factor NF-B (46). CD14 is shown to be required for functional MyD88-
independent LPS-mediated signalling (47), and CD14/TLR4/MD-2 and TLR4/MD-2 
without CD14 are shown to discriminate and react differently to various types of LPS 
(48). As TLR4 is widely distributed, while CD14 expression is by far limited to 
myeloid-derived cells, these LPS discriminating properties suggest that different types 
of LPS will activate various cells differentially (48). When activated, the cells produce a 
range of proinflammatory cytokines which drive the inflammatory resonse (49, 50). 
Interestingly, the key downstream molecule MyD88, is shown to be more homologous 
between humans and pigs than humans and mice, which may be of importance studying 
and interpreting LPS-signalling data in these model animals, suggesting the pig to be 
the better suited (51). 
 
1.1.4 The complement system 
 
The complement system consists of more than 30 proteins mainly found in plasma but 
also bound to cell surfaces (52). It is named so because it was identified as a heat-labile 
component in serum “complementing” the heat-stabile antibodies in the killing of 
bacteria (53). The system is ancient and is both preserved and developed in evolution 
(54). It is a cascade system in plasma, and is activated by three distinct pathways: The 
classical pathway (CP), the lectin-pathway (LP) and the alternative pathway (AP) (55). 
The CP is activated by C1q binding to immunoglobulins (52), particularly IgM, but also 
other molecules like C-reactive protein (CRP) and phosphatidylserine with importance 
for clearance of apoptotic cells (56, 57). The LP is activated by mannose-binding lectin  
and ficolins binding to in particular carbohydrate structures (58, 59). The AP pathway is 
continuously activated by hydrolysis of C3 and triggered by a range of different 
compounds like lipids, carbohydrates and proteins (60). In the 50’s properdin was 
proposed as an initiator of this pathway and recent evidence supports these early 
findings (61, 62). Another and very important function of the AP is amplification of the 
complement respons initiated by the other two pathways (63). All the recognition 
molecules of the complement system (e. g. C1q, MBL, ficolins and properdin) are 
PRRs, as they recognize PAMPs and alarmins and mediate the danger signals through 
complement-activation (8).  
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The cascade initiated by all three pathways leads to formation of the C3-convertase and 
thereby the C5-convertase and the end-product of the final common pathway is the 
terminal C5b-9 complement complex (TCC). TCC exists both in the fluid-phase or 
inserted into membranes, where it is often called the membrane-attack complex (MAC). 
The CP and LP both activate serine proteases which cleaves C4 and C2 and forms the 
C3 convertase C4b2a. C4b2a cleaves C3 to C3a and C3b and forms the C5 convertase 
C4b2a3b. The AP forms C3b by the mentioned hydrolysis. C3(H2O) binds factor B 
which is then cleaved by factor D to C3(H2O)Bb. C3(H2O)Bb cleaves C3 to C3a and 
C3b. C3b binds factor B and the second C3 convertase, C3bBb forms. The alternative 
pathway C5 convertase, C3b3bBb is then formed by binding another C3b. C5 is cleaved 
by either C5 convertase and forms C5a and C5b. C5b binds C6 and the complex bind 
C7, C8 and nC9 and forms the TCC (52, 64). 
 
The main function of the complement system is to detect and kill microorganisms, as 
well as maintain homeostasis through clearance of apoptotic cells and cell debris, and 
tissue regeneration (65-68). Opsonization by C3b leading to phagocytosis is the most 
important mechanism, but for some pathogens like Neisseria-species, killing by direct 
lysis by the MAC is equally  important (69). The products of the complement system 
have however a number of other effects. C5a is an important mediator of inflammation 
as discussed later, and TCC and other complement proteins are involved in cell death 
(apoptosis and necrosis), clearance of apoptotic cells and cell activation (66, 70). A 
number of soluble and cell-bound regulatory proteins act to inhibit the complement 
system, keeping it under tight control (71).  
 
1.1.5 Complement and inflammation 
 
Complement activation initiated by any of the three pathways leads to inflammation 
(72, 73), with the exception of the role of complement in removal of apoptotic cells 
(70). The primary inflammatory effects by the complement system could be dived into 
receptor- and non-receptor mediated effects. The secondary inflammatory effects 
induced by complement develop during processes like C3b-opsonized phagocytosis. 
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Important receptor-mediated inflammatory effects come from C3a and C5a, called 
anaphylatoxins, and are produced as split products of the complement cascade and bind 
to specific reseptors on cells (74). C4a is also traditionally recognized as one of the 
anaphylatoxins, but no receptor for the molecule or biological effect is known (74). A 
recent report, however, has shown direct antimicrobial properties of C4a, which may 
have importance in the antimicrobial defence (75). C3a has been implicated in 
inflammation through binding to its receptor C3aR, which is particular abundant 
expressed on mast cells and eosinophils (65). A particular focus concerning C3a-
mediated inflammatory effects, has been on lung diseases like asthma and ARDS (76).  
C3a is also found to have importance in other inflammatory conditions, like I/R-injury 
in the kidneys (77). C5a is the key inflammatory mediator of the anaphylatoxins and 
probably of all the complement components. It is a peptide with a molecular weight of 
11 kDa and it binds to the C5aR (CD88) and to the C5L2 receptor (78, 79). It is rapidly 
degraded to the less potent C5a desArg which also binds to C5aR and C5L2 (79). The 
effects of binding of C5a or C5a desArg to their receptors depend on the cell type 
expressing them. C5a is known to have a range of effects on the innate immune cells in 
particular neutrophils and macrophages: it is a chemoattractant and enhance expression 
of adhesion molecules on the cells both of which are important to direct the phagocytes 
from the blood to the site of infection/injury (80, 81); the molecule induce phagocytosis 
and the consecutive oxidative burst to kill the phagocytized microorganisms (64), and it 
releases enzymes from intracellular granules as well as induces production and release 
of cytokines (82-84). The effect of C5aR binding of C5a is most extensively studied 
while the role of C5L2 is less well understood, although recent studies have indicated 
both important pro- and anti-inflammatory effects of the C5L2 receptor (85, 86). C5aR 
is also expressed on endothelial cells, where binding of C5a leads to proinflammatory 
effects like upregulation of the adhesion molecule P-selectin (87), as well as production 
of cytokines and the important inductor of coagulation, tissue factor (TF) (88, 89).  
 
The non-receptor mediated primary inflammatory effect of complement activation is 
mediated by TCC (MAC) inserted into membranes. The insertion leads to Ca2+-influx 
which acts as a second messenger, and effects like adhesion molecule upregulation and 
release of inflammatory mediators may be induced (70).One study has proposed a 
primary receptor-mediated inflammatory effect by the soluble TCC via binding to a 
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vitronectin receptor (90), but the possible role of this interaction has not been further 
described. 
 
The complement system is implicated in the pathogenesis of both acute and chronic 
inflammatory diseases. The role of complement activation has been shown to play an 
important part in the pathogenesis of acute inflammatory conditions like I/R-injury (91), 
meconium aspiration syndrome (MAS) (92), trauma (93) and sepsis (94). In addition 
complement is involved in chronic inflammatory diseases like glomerulonephritis and 
rheumatoid arthritis (95-97).   
 
 
 
Figure 1. The Complement System (Mollnes TE, Song WC, Lambris JD 2002 
Complement in inflammatory tissue damage and disease. Trends Immunol 23:61-64, 
with permission from Elsevier) 
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1.2 Sepsis 
1.2.1 Definition 
 
Sepsis could be defined as systemic inflammatory response syndrome (SIRS) caused by 
infection (98), as systemic inflammation could be induced by a variety of severe 
conditions other than infections, like burns and trauma. The initial SIRS definition was 
two or more of: temperature > 38 ºC or < 36 ºC, heart rate > 90 beats/min, respiratory 
rate > 20 breaths/min or PaCO2 < 4.3 kPa, WBC > 12 x 109/ L or < 4 x 109/ L or > 10 % 
immature forms (98). In this concensus article definitions of categories based on 
severity in sepsis were also proposed. The categories suggested were sepsis, severe 
sepsis, septic shock and multiple organ dysfunction syndrome (MODS) (98). The sepsis 
definition was, however, found to be overly sensitive and non-spesific and a new set of 
more detailed criteria was therefore proposed, for details see Levy et al. (99). Another 
staging of sepsis called PIRO (Predisposition, Insult (infection), Response, and Organ 
dysfunction) was also presented (99). The challenge of a clear definition and staging of 
sepsis is however still present, a particular demanding area is inclusion of homogenic 
sepsis populations in clinical trials (100). Further improvement and revision of the 
present definitions of sepsis seems to be mandatory (101). 
 
1.2.2 Epidemiology – Sepsis and Gram-negative sepsis 
 
Recent studies from European countries show an incidence of sepsis in the adult 
population of 75 to 350 per 100,000 per year (102, 103). Figures from the USA show an 
incidence of 130 to 240 per 100,000 per year (104, 105), and 1.3% of all 
hospitalizations in the US over a 22-year period was due to sepsis (104). The mortality 
rates range from 10 % for sepsis in general to 50 % for severe sepsis (16, 102, 103).  
 
Gram-negative bacteria as the causative pathogen in sepsis have declined in recent 
years, but is still a major cause of the syndrome, counting for approximately 25 to 40 % 
of all cases (104, 106). Escherichia coli (E. coli) is on of the most frequent causative 
Gram-negative bacteria , with a frequency of 13 % of all cases in the Sepsis Occurrence 
in Acutely Ill Patients (SOAP) study (107). A frequency of  E. coli of up to 27 % of the 
total causative pathogens in sepsis has been reported (106). E. coli strains showing 
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multidrug resistans to antibiotics are an increasing problem and a major concern in 
infectious disease and sepsis care (108). 
1.2.3 Risk factors 
 
The occurrence of sepsis in adults peaks in the sixth decade of life (102, 103). Factors 
that can predispose to sepsis are cancer, primary, acquired or pharmacologically 
induced immunodeficiency, chronic organ failure, and iatrogenic factors like surgery or 
catheters (106). Pulmonary, gastrointestinal, urinary and skin infections are the leading 
origins leading to sepsis (103). However, the origin of the infection is often hard to 
reveal. Recurrently found clinical risk factors independently associated with mortality in 
sepsis are adequacy of antibiotics, underlying disease, source and type of infection, 
presence of shock, need for vasopressors, multiple organ failure, and neutropenia (109). 
Research on genetic factors predisposing to sepsis has revealed polymorphisms that 
may predispose to or protect against the syndrome, but unfortunately many of these 
studies have been underpowered and often provided weak indications or contradictory 
results (110). Despite this, interesting data has emerged from the genetics field. For 
instance is quantitative or functional deficiency of on of the complement systems PRR, 
MBL, associated with  development of sepsis (111). 
 
The search for biomarkers that can help diagnose sepsis and predict the outcome of the 
syndrome has been intense. Long lists of candidates have been made, see for instance 
Lever et al. (112), and new ones are added rapidly to those lists. As sepsis is a syndrome 
and involves almost all defense systems in the body, the complexity is enormous and 
finding single mediators to predict the prognosis or outcome have thus been hard. 
 
1.2.4 Treatment 
 
Treatment of sepsis and in particular treatment of severe sepsis and septic shock is 
multifactorial and may be divided into two main cathegories: antibiotics and supportive 
therapy. International guidelines founded on consensus conferences and evidence-based 
studies have been made. Guidelines published in 2008 recommend early treatment with 
broad-spectrum antibiotics (if the microbe is not known) and initial resuscitation (first 
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six hours) as the first line of treatment (113). Better diagnostics of the causing 
microorganism, in order to optimize the treatment, is desirable as the nature of the 
pathogens influence the host response (114). In addition to the treatment of the causing 
microbe, hemodynamic support is the most essential in the sepsis treatment. To 
maintain central blood flow and pressure, fluid therapy, vasopressors and inotrops are 
recommended. Additionally, supportive measures like mechanical ventilation, blood 
product administration, sedation and analgesia, glucose control, and corticosteroid 
administration may be used if needed (113).  
 
Specific treatment of the complex and potential lethal inflammatory response in sepsis 
has been long sought. Numerous single mediators of inflammation have been targeted in 
the quest for a potent “wonder-drug”. Promising results have been obtained from 
experimental studies, but results from clinical trials for instance targeting and 
neutralizing TNF- have been disappointing (115). This paradox made one author write 
a review paper heading that spoke for itself: “Such stuff that dreams are made of: 
Mediator-directed therapy in sepsis” (116). Recombinant human activated protein C 
(rhAPC) has maybe been the most promising candidate for mediator directed therapy in 
sepsis, but clinical trials have not been able to provide sufficient evidence to justify 
general use of rhAPC in sepsis (117-119). Present guidelines recommend use of rhAPC 
in adult patients with high risk of death (113).  
1.3 Inflammation in sepsis 
  
The inflammatory response in sepsis is vast and complex. All the main cascade systems 
in the blood, the coagulation system and the fibrinolytic system (120, 121), the 
complement system (55, 122), and the contact system are activated (123), along with 
the main innate immune cells monocytes/macrophages and neutrophils (124, 125). 
Subsequently, the adaptive immune system will also be engaged in the development of 
the syndrome. In particular, the adaptive immune system has shown to shift from a TH1- 
to a TH2-cell driven response leading to profound immunosuppresion in the later phase 
(126), as well as to dampen the innate immune response in the early phase of sepsis 
(127, 128). Other cell and organ systems like endothelium (129), the endocrine system 
and the autonome nervous systems have shown to be important players in the 
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devastating sepsis game (130, 131). The development of an imbalance in the network of 
all these systems is thought to be responsible for the harmful loss of control of 
inflammation in sepsis. Crosstalk between the systems seems to be an integrated and 
pivotal part in the inflammatory drive. Examples of such crosstalks in inflammation are 
increasing and the research in this field is expanding. For instance has thrombin of the 
coagulation cascade been shown to directly cleave C5 of the complement system to C5a 
in the absence of C3 (132), indicating that C5a and TCC may be generated in the 
absence of upstream complement activation. C5a has been shown to induce the spark 
plug of coagulation, TF, both on endothelial cells and neutrophils (89, 133). The 
nervous system may both enhance and inhibit inflammation in a close crosstalk with 
innate immune cells (134). These are just a few of many examples of crosstalks 
important to be aware of when studying inflammation in sepsis. 
 
 
Figure 2. Crosstalk in Gram-negative induced inflammation  
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2 Aim 
 
To investigate the effect of inhibition of Gram-negative induced inflammatory response 
by targeting two main innate immune upstream effector pathways, complement and 
CD14, in a pig model. 
 
2.1 In vitro 
 
1. To investigate the effect of known inhibitors of human complement  in a porcine in
vitro serum model, and compare the candidate inhibitors effect on different activators of 
complement using TCC as a marker of complement activation.  
 
2. To establish a newly developed human in vitro whole blood model in porcine blood, 
and to use this model to investigate an anti-porcine CD14 antibody and Orthopox-viral 
derived complement inhibitors on E. coli LPS- or whole live bacteria-induced 
inflammatory response, and thereby the different roles of the CD14/TLR4/MD-2-
complex and complement in this inflammatory response. 
 
3. To study the potential of inhibiting E. coli LPS-induced inflammatory response by a 
Cyanobacterial LPS analog (CyP) known to bind to the (CD14)/TLR4/MD-2 LPS-
receptor complex. 
 
2.2 In vivo 
 
1. To establish a porcine in vivo model of whole live E. coli bacteria-induced 
sepsis/inflammation with focus on mediators of the early inflammatory response 
induced by the bacteria. 
 
2. To use the porcine in vivo model to investigate the inhibitory effect of the anti-
porcine CD14 antibody on whole live E. coli bacteria-induced inflammatory response in
vivo, including markers of hemostasis and granulocyte activation.
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3 Material and methods 
3.1 Introduction 
 
The purpose of this part of the Thesis is to to give a cross-sectional and superior view of 
the material and methods used. For detailed description of reagents and methods please 
see the material and methods sections in each paper.  
 
3.2 Inhibitors 
 
Several unique inhibitors not commercially available were used in the studies. The 
Orthopox-viral encoded complement inhibitors VCP and SPICE were used in study I 
and II. The complement inhibiting monoclonal antibodies anti-factors B and D were 
used in study I. CyP, a product from blue - green algae was used in study III. The 
protease complement inhibitors C1-inhibitor and FUT-175 (study I), and the 
monoclonal anti-CD14 antibody (study II and V) were commercially available and 
purchased for the studies. The reagents not commercially available were provided by 
international collaborators. 
 
3.3 Analyses 
 
3.3.1 ELISA 
 
The TCC assay is a so-called “sandwich” ELISA based on the human antibody aE11 as 
capture antibody in the wells. aE11 recognize a neoepitope on complement component 
C9 exposed after incorporation in the TCC (135), and thereby complement activation. 
aE11 and the detection anti-C6 antibody are shown to cross-react with porcine C9 and 
C6 respectively (136, 137), and the assay could therefore be used to detect porcine TCC 
(study I-IV). Normal human serum activated with zymosan and defined to contain 1000 
arbitrary units (AU)/mL was used as standard, while zymosan activated porcine serum 
was used as positive control.  
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The porcine cytokines TNF-, IL-1 and IL-8 (study II-V) were detected under the 
conditions used both in vitro and in vivo. IL-6, however, was detected in vivo (study IV-
V) but only in vitro using a high dose LPS (study III). IL-10 (study IV-V), IL-12 and 
VEGF (study IV) were only detected in vivo. HMGB-1 was not detected in the studies. 
The cytokines were analysed by commercially available ELISA kits. The numbers of 
such kits available for pigs are limited compared to humans and mice. This restricted 
the number of cytokines possible to detect in the studies. 
 
Citrate plasma was used in the analysis of coagulation and fibrinolysis. TAT was 
detected in a commercial available human ELISA proved to be applicable in porcine 
plasma (138) (study IV-V). PAI-1 was detected by a commercial available porcine PAI-
1 ELISA (study V). 
 
3.3.2 Flow cytometry 
 
CD14 and wCD11R3, a porcine analog to human CD11b, was detected on granulocytes 
by flow cytometry both in vitro (study II) and in vivo (study V). It would have been 
interesting to look at these cellular markers on monocytes as well, in particular 
wCD11R3 as previous human studies have shown differences in upregulation and 
inhibition experiments on CD11b expression between granulocytes and monocytes 
(139). Unfortunately, it is not possible to separate pig monocytes and lymphocytes by 
gating in flow cytometry, in contrast to what is the case with human monocytes and 
lymphocytes. 
 
Hematological parameters were analysed on one of the hospital’s routine hematological 
instruments, which is in principle a flow cytometer. 
 
 
3.3.3 Microbiological analyses 
 
CFUs were measured both in vitro (study II) and in vivo (study IV). CFUs were readily 
detectable in vitro and the time-dependent effects of the inhibitors of complement and 
CD14 could be studied. The method seemed realiable for this purpose in vitro, as two 
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separate experiments from two different pigs were virtual identical (study II). In vivo, 
however, only trace amounts of bacteria were detectable by this method. Even after a 
large bolus of bacteria was injected, only a few bacteria were detected in the blood after 
10 minutes (study IV). The method was therefore omitted in the in vivo study V.  
 
A novel E. coli DNA detection analysis applied in study V was developed. Based on 
SeqA primers, E. coli DNA could be detected and quantified by real-time PCR. The 
primers were not E. coli specific as they also detect Shigella species and Salmonella
enterica DNA, but this was not a problem for our purpose. CFU counts are very useful 
to detect living bacteria, while DNA analyses detect both living and killed/disrupted 
ones. The methods complement each other and it is important to be aware of their 
advantages and limitations.  
 
LPS was detected by an endpoint chromogenic method in a Limulus Amebocyte Lysate 
(LAL)-assay (study V). The LAL-assay is based on a protein cascade which is activated 
by LPS and ultimately cleaves a peptide substrate which liberates a yellow substance (p-
nitroaniline). The yellow colour can be measured directely. But as we measured LPS in 
serum which absorbs at the same wavelength as p-nitroaniline (405-410 nm), a diazo-
coupling modification was used to change the detection colour to magenta (absorbs at 
540-550 nm).  
 
Alexa FLUOR 488 stained E. coli was injected into two pigs in study V and 
immunofluorescent histology of cryo-sections cut from the lung and liver biopsies was 
performed, and E. coli were qualitatively detected in the tissues. 
 
3.3.4 Gelatine zymography 
 
Matrix metalloproteinase (MMP)-9, a protease released by activated granulocytes and 
monocytes, was detected by gelatine zymography (study IV and V). Pictures were taken 
of the gels and activity of MMP-9 in the gels was quantified by special software. It was 
important to analyse samples that were going to be statistically compared in the same 
run, as inter-assay runs could differ substantially. 
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3.4 Models 
3.4.1 In vitro model 
  
The first part of the in vitro studies was conducted in serum. Serum was prepared from 
three healthy pigs and tested in Wielisa for assessment of complement functional 
activity in classical, lectin, and alternative pathway (140). The assay is based on the 
human monoclonal detection antibody aE11, known to cross-react with pigs (136, 137), 
and a lower serum dilution was used to optimize conditions when testing pig serum 
(137). The sera were pre-incubated in polystyren tubes at 37 ºC for five minutes with 
complement inhibitors and then activators of complement were added and incubated for 
another 30 minutes (study I). Complement activation was stopped after incubation by 
adding ethylenediaminetetraacetic acid (EDTA) and the sera were stored at -70 ºC 
before analyses. 
 
The second part of the in vitro studies was conducted in whole blood. Whole blood 
from healthy pigs was anticoagulated with the specific thrombin inhibitor lepuridin 
(Study II-III). The method is described previously in human whole blood (64) and were 
proved to work in pig whole blood as well. The whole blood was incubated in 
polypropylene tubes with inhibitors of complement or the CD14/TLR4/MD-2 LPS-
receptor for five minutes at 37 ºC and then E. coli LPS or whole E. coli bacteria were 
added and incubated for 10 (flow cytometry detection of CD14 and wCD11R3), 30 
(TCC), 120 (TNF-, IL-1 and TCC) or 240 (IL-8 and CFU experiments) minutes at 
37 ºC. Complement activation was stopped after incubation by adding EDTA, plasma 
was prepared and the samples were stored at -70 ºC before analyses. 
 
3.4.2 In vivo model 
 
A pig model was developed to study Gram-negative bacteria induced inflammation in 
vivo (study IV). Norwegian farm pigs of out-bred stock (Sus scrofa domesticus) were 
used in the studies. In study IV, 30 kg pigs were used, and the model was slightly 
modified in study V where 15 kg pigs were used. They were aneasthetized and surgery 
conducted as described in study IV. The pigs were hemodynamically and respiratory 
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extensively monitored, including blood pressures (CVP, MAP, MPAP, and PAOP), 
respirator settings and blood gases. An important difference between the pigs and the 
humans, however, are found in the reticuloendothelial system (RES). The pig has 
resident macrophages in the lung (141), closely resembling the Kupffers cells found in 
the human liver. When administering E. coli IV to the pigs, we experienced a rapid rise 
in MPAP, not so commonly seen in human sepsis. The high MPAP experienced was 
probably due to mediators like prostacyclins and –glandins and leukotriens released by 
the lung macrophages (141), leading to vasoconstriction locally in the lungs. The 
increased pulmonary pressure was problematic for the model, as circulation was 
compromised. However, rescusitation with physiological saline water (volume therapy) 
(study IV-V) and occationally norepinephrine administration (study V) made the 
experiments possible to conduct. This difference between pigs and humans is important 
to be aware of when interpreting data from pig sepsis models, especially data on 
circulation physiology. 
 
3.5 Statistical considerations   
 
In the experiments where the data “spoke for themselves”, no statistics were used. This 
applied to all the data in study I and the majority of the data in study II and III.
 
The non-parametric Mann-Whitney U test was used for a couple of data sets in study III 
and V, and is the non-parametric counterpart to the parametric two-sample t - test. In 
study III, the test was used on the data presented in Table 1. As there was skewness in 
these data, a normal distribution could not be assumed and thereby could parametric 
tests not be used (142). In study V, the Mann-Whitney U test was used on the data 
presented in Figure 7. Some of the data were below the “cut off” for the analysis; these 
data were given arbitrary values and could be used in a rank test. Parametric tests could 
not be applied to such data.  
 
A two-sample t – test for independent samples were applied in study II (Figure 6) and V
(Figure 2, 4 and 5). There were no skewness in the data and they could thereby be 
assumed to be normal distributed, although one might criticize this assumption as the 
number of experiments was low (n ~ 6) in all these data sets.  
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 In study IV and V more complicated methods were applied. Several parameters were 
measured repeatedly over the time course of the in vivo experiments. Hence, the data 
were not independent of each other and tests which assume independence of the data, 
like the t – test, could not be applied. A mixed model was applied in study IV. It is a 
flexible modern form of regression analysis and is well suited to look at group effects 
developing over time. Both random (e. g. different baseline values) and fixed effects 
(e. g. group) are taken care of in such models (143). However, mixed models are 
complicated and we needed help from a statistician to conduct the calculations. In study 
V we used a two-way ANOVA with repeated measures. A mixed model as used in 
study IV could not be applied as the number of animals was too low. The main effect 
(treatment with anti-CD14) over time was tested (interaction treatment and time) 
between the treatment and the positive control group. 
 
In all the tests in this Thesis, a significance level of P < 0.05 was chosen. In other words 
it was a 5 % chance of rejecting the null hypothesis when it was true, a so called Type I 
error (144). This is in general an accepted Type I error risk in medical statistics, but 
lower significance levels like P < 0.01 are sometimes seen, reducing the risk of such an 
error. However, the lower the significance level the greater the risk of making the other 
mistake in significance testing, the Type II error. The Type II error is to fail to reject the 
null hypothesis when it is in fact false. The propability of not making a Type II error is 
called power. The higher the power is the less the risk of making a Type II error. This 
can be achieved by a high sample size and/or precise measurements. In this Thesis the 
number of samples in both the in vitro and the in vivo experiments was limited due to 
limited amounts of the unique reagents (e. g. complement inhibitors and anti-CD14). 
The risk of making Type II errors was therefore, considering, probably greater than the 
risk of making Type I errors. 
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4 Summary of results  
 
Paper I: The serine protease inhibitor FUT-175 inhibited porcine complement 
activation measured as TCC to baseline levels at all concentrations used for all the three 
activators of complement, HAIGG, zymosan and E. coli.The other serine protease 
inhibitor tested, C1-INH, inhibited complement completely at the highest dose added, 
and inhibited HAIGG- and E. coli-induced complement activation more efficiently at 
lower doses than was the case for zymosan-induced activation. The monoclonal anti-
factor B dose-dependently and almost completely inhibited zymosan- and HAIGG-
induced complement activation, while E. coli-induced complement activation was not 
inhibited by the antibody. The monoclonal anti-factor D inhibited complement 
activation by all three activators by approximately 50 %. The recombinant Vaccinia-
virus complement control protein, VCP, was the most specific candidate inhibitor of 
complement tested. It dose-dependently and completely inhibited complement 
activation by all three activators. On a molar basis, taking into account the lowest dose 
of each inhibitor which gave the best inhibition, VCP was the most efficient 
complement inhibitor of the ones tested. 
 
Paper II: An anti-porcine CD14 monoclonal antibody dose-dependently saturated 
CD14 on granulocytes in porcine whole blood. Anti-CD14 was then shown to dose-
dependently and completely inhibit E. coli LPS-induced production of the 
proinflammatory cytokines TNF-, IL-1 and IL-8. Complement was activated by 
whole live E. coli bacteria in porcine whole blood, in the same manner as shown for 
complement activation in porcine serum in study I. VCP was shown to dose-
dependently and completely inhibit E. coli induced complement activation in whole 
blood and thereby confirming the potent complement inhibitory effect of the protein, 
shown in study I. SPICE, another Orthopox-viral derived complement inhibitory 
protein, was shown to be approximately five times more potent than VCP. wCD11R3, 
the porcine analog to human CD11b which together with CD18 forms the iC3b-binding 
CR3-phagocytosis reseptor, was shown to be dose-dependently upregulated by E. coli 
on granulocytes in porcine whole blood. The upregulation was dose-dependently and 
completely inhibited by VCP but not anti-CD14, showing that this upregulation was 
complement-dependent. Bacterial clearance measured as CFU was shown to be partly 
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complement-dependent as SPICE but not anti-CD14 inhibited the clearance. Whole E.
coli-induced TNF- and IL-1 was dose-dependently and significantly (P < 0.05 and P
< 0.01 respectively) inhibited by anti-CD14 but not SPICE, IL-8 was dose-dependently 
and significantly (P < 0.05) inhibited by SPICE but not anti-CD14, showing that TNF- 
and IL-1 were dependent on CD14 and IL-8 on complement. Thus, both complement 
and CD14 inhibition were shown to attenuate E. coli-induced inflammation in whole 
blood in vitro. 
 
Paper III: CyP, a Cyanobacterial derived LPS analog, did not induce production of the 
proinflammatory cytokines TNF-, IL-1, IL-6 or IL-8 when incubated in porcine 
whole blood. E. coli LPS added in the same amount induced production of the same 
cytokines. CyP dose-dependently and completely inhibited E. coli LPS-induced 
production of TNF-, IL-1 and IL-8 in porcine whole blood. CyP reduced whole live 
E. coli bacteria-induced cytokine production, but to a lesser extent than LPS-induced 
production. The best inhibitory effect was seen on IL-1 production, where CyP 
reduced the production by 44 %. CyP was found to be a moderate inductor of porcine 
complement measured as TCC, compared to LPS from K. pneumoniae, S. typhosa and 
E. coli. LPS from N. meningitides was found to be the least potent complement activator 
of the LPS types, including CyP, tested. At doses below 10 μg CyP/mL whole blood, 
the dose needed for complete LPS-induced cytokine inhibition, no complement 
activation was observed. In summary, the TLR4/MD-2 inhibitor, CyP, was shown to be 
an efficient inhibitor of E. coli LPS-induced inflammation in whole blood. 
 
Paper IV: A pig model of acute sepsis with focus on the early inflammatory response 
and biomarkers of this response was developed in order to use it for interventional 
studies based on in vitro findings from study I-III in the future. Healthy 30 kg pigs were 
challenged with whole live E. coli bacteria either intravenously (IV) (n = 12) or 
intrapulmonary (IP) (n = 6). Control pigs received bacterial culture medium (n = 6 + 3). 
Haemodynamic compromise, as seen in sepsis and septic shock in humans, was also 
seen in this pig model. Aggressive fluid rescusitation was done in order to maintain 
MAP above 65 mmHg. Due to this, the pigs did not develop signs of hypoperfusion, 
like increased blood lactate. In the IV arm TNF- (P = 0.006), IL-6 (P = 0.005), IL-8 (P
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= 0.033), IL-10 (P < 0.001) and IL-12 (P = 0.012) increased significantly in the E. coli 
group compared to the culture medium group. IL-1 also increased, but failed to reach 
significance (P = 0.063). No significant differences between the cytokines were 
detected in the IP arm. A marker of coagulation, TAT, incresead significantly in the IV 
arm E. coli group compared to the control group (P < 0.001). MMP-9, an enzyme which 
is released from granulocytes and enzyme-activity increases during inflammation, 
increased in the E. coli group in both the IV and IP arm compared to the control group. 
The increase came earlier in the IP arm than in the IV arm. Complement activation and 
CFUs were only to a minor extent detected in this model. In conclusion, this pig model 
provided new insights into the early inflammatory response in experimental sepsis. 
 
Paper V: The study was based on the pig E. coli sepsis model developed in study IV. 
Pigs were challenged IV with either whole live E. coli bacteria or E. coli LPS. The anti-
CD14 antibody studied in vitro in study II was shown to completely and significantly 
saturate CD14 on granulocytes in vivo compared to the positive control group (P < 
0.0001) and the saturation was sustained throughout the observation periode in both the 
E. coli-and the LPS-arm. TNF- (P = 0.032), IL-1 (P = 0.008) and IL-6 (P < 0.0001) 
were significantly reduced by anti-CD14 in the E. coli-arm, while IL-8 was completely 
inhibited by anti-CD14. TNF-, IL-6 and IL-8 were reduced in the same manner in the 
LPS-arm, while IL-1 values were around the lower detection limit in both the anti-
CD14 and control groups. IL-10 showed a different time course in the anti-CD14 group 
compared to the positive control group in the E. coli-arm but not in the LPS-arm. In the 
E. coli-arm IL-10 increased later than the other cytokines, but reached levels higher than 
in the positive control group. MMP-9 increased in both the E. coli- and the LPS-arms, 
but not in the negative control groups. The increase came earlier in the LPS-arm. MMP-
9 was significantly reduced (P = 0.003) after 120 minutes in the anti-CD14 group in the 
E. coli-arm, but not in the LPS-arm. wCD11R3 on granulocytes were significantly (P = 
0.008) reduced after 180 minutes in the anti-CD-14 group in the E. coli-arm and the 
same trend was seen in the LPS-arm. There were no differences in LPS-levels between 
the anti-CD14- and positive control-groups in either arm of the study (P = 0.81 in the E.
coli-arm). No difference was detected between the anti-CD14- and positive control 
groups (P = 0.37) in E. coli-DNA levels in the E. coli-arm. E. coli-DNA was not 
detected in the LPS-arm. The marker of coagulation, TAT, was significantly (P = 0.011) 
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inhibited by anti-CD14 in the E. coli-arm. The same was the case for the suppressor of 
fibrinolysis, PAI-1, which was significantly (P = 0.005) inhibited by anti-CD14 in the 
E. coli-arm. In summary, CD14-inhibition efficiently attenuated the proinflammatory 
cytokine response and granulocyte activation, reversed the pro-coagulant state, but did 
not interfere with LPS levels or bacterial counts in experimental E. coli-induced sepsis 
in vivo. 
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5 Discussion  
 
5.1 Activators of inflammation 
5.1.1 LPS 
 
LPS of Gram-negative bacteria consists of a lipid A moiety, a short core 
oligosaccharide and an O-polysaccharide of variable length. LPS with O-
polysaccharides is called smooth LPS, while LPS without O-polysaccharides is called 
rough LPS. The LPS molecule varies substantially among the Gram-negative bacteria 
and among different strains of each bacterium. Additionally, Gram-negative bacteria 
have several enzymes that can modify LPS in theire membranes (145). It is accordingly 
a vast diversity of LPS types.The purity of the LPS is another important feature to keep 
in mind when studying LPS responses through the TLR4 pathway. It is shown that 
contaminants, like lipoproteins, in crude LPS preparations signals through the TLR2- as 
well as the TLR4 pathway (146). The LPS used in study II, III and V was treated by 
phenol-extraction by the manufacturer and was so-called ultra-pure. It thereby only 
binds to and signals through the TLR4 receptor complex, which was the intention in this 
Thesis. 
 
5.1.2 Whole live Escherichia coli bacteria 
 
The use of LPS to mimic Gram-negative sepsis and septic shock is common and LPS is 
recognized as important in the pathogenesis of Gram-negative sepsis (147). However, 
live Gram-negative bacteria have properties that LPS can not mimic. We showed in 
study II that the bacteria devided when incubated at 37 ºC in vitro and additionally live 
E. coli bacteria were retrived after 240 minutes in vitro incubation in whole blood. 
Thus, dynamic features of the living bacteria in contact with the host can not be found 
in LPS models. Although LPS is pivotal, other ligands on Gram-negative bacteria could 
also contribute to the pathogenesis of inflammation and sepsis. It is for instance shown 
that LPS-deficient N. meningitides (LPS-) can activate the complement system and 
induce complement mediated inflammatory effects (148). N. meningitides (LPS-) have 
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also been shown to be able to induce large gene expression changes in human 
monocytes (149). In study II, we found that anti-CD14 inhibited production of LPS-
induced IL-8 production in whole blood, but not whole live E. coli-induced IL-8. In 
study III, CyP was shown to efficiently inhibit LPS-induced proinflammatory cytokines 
to baseline levels, while the effect on E. coli-induced production of the same cytokines 
was moderate. We therefore argue that experiments with whole live bacteria, as 
conducted in this Thesis, give additional information to LPS in studies of Gram-
negative inflammation and sepsis. 
 
5.2 The inhibitors used 
 
5.2.1 Complement inhibitors 
 
A range of complement inhibitors have emerged over the last two decades, and the 
awareness of the potential of inhibiting complement in inflammatory diseases like 
sepsis is increasing (150, 151). Several promising studies have been conducted in rodent 
sepsis models. C1-INH has shown to protect against CLP-induced sepsis in mice (152), 
although much of the protective effect of this inhibitor is probably not complement 
mediated (153). Inhibition of Crry, a rodent C3 convertase inhibitor, induced lethal 
endotoxin shock in rats, showing the protective role of this membrane bound 
complement inhibitor (154). C5a is emerging as a key molecule in sepsis and inhibition 
of C5a in rodent sepsis models has shown a protective role, see for instance Huber-Lang 
et al. (155), or Flierl et al. (156). Anti-C5aR or anti-C5L2, both C5a receptors, have 
shown protective effects in a rat CLP sepsis model (157). In contrast to rodents, studies 
addressing porcine complement inhibition in general and in sepsis particular have been, 
with a few exeptions like Mohr et al. (158), scarce. In study I, this need was addressed 
as complement inhibitors of three main cathegories (serine protease inhibitors, 
monoclonal antibodies, and a recombinant protein) were tested as inhibitors of 
complement activation in a “pure” in vitro system in porcine serum. Interestingly, 
human reagents like C1-INH and murine reagents like anti-mouse factor B showed 
effect in pig serum. Particularly, VCP, a protein derived from the Orthopox-virus 
Vaccinia, showed impressing complement inhibitory effect on complement activated by 
three different potent complement activators (HAIGG, zymosan and E. coli). In study 
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II, porcine complement inhibition by VCP was confirmed in a more “complex” in vitro 
system, whole blood. Another Orthopox-viral derived protein tested in study II, SPICE, 
was shown to be an even more potent complement inhibitor than VCP. Thus, this Thesis 
has provided novel information on complement inhibitors which can be used in pig 
sepsis models and pig models of human diseases in general. 
 
5.2.2 Inhibitors of the TLR4 complex 
 
CD14 is a central molecule in the LPS-receptor complex. It was first thought that all 
LPS types was transferred by LBP to CD14 and that CD14 indiscriminatly delivered the 
ligand to TLR4, a process that concentrated the LPS signal (18). It is, however, revealed 
that CD14 is essential for proper recognition of smooth LPS, the commonest form of 
LPS expressed by Gram-negative bacteria, but not rough LPS (47). CD14 is thereby 
thought to be a highly specific receptor and responsible for at least part of the ligand 
specificity of the LPS-receptor complex (41). CD14 has thus been named “the smooth 
operator” for LPS reponses (48). LPS from E. coli strains are smooth (159). CD14 
would according to these findings by Jiang and Gangloff (41, 47), be essential for 
recognition of and signaling by the E. coli LPS used in study II, III and V in this 
Thesis. Inhibiting CD14 in order to reduce smooth LPS-induced inflammatory 
responses might therefore be more effective than inhibiting TLR4. CD14 is also known 
to be a co-receptor for other TLRs in addition to TLR4, for instance for TLR2, a 
receptor for lipoproteins/peptides from all kinds of bacteria, and the intracellular TLR3 
(43, 160). Although a recently published study showed impressive effect of an anti-
TLR4 antibody in a murine model of E. coli-sepsis (161), one might claim that CD14 is 
a more upstream and general target for inhibition of inflammation than TLR4.  
 
The anti-porcine CD14 antibody clone MIL-2 used in study II, III and V, has 
previously been found to inhibit binding of LPS (162). In this Thesis, the anti-CD14 
monoclonal antibody was functionally characterized. It was found to bind to CD14 on 
porcine granulocytes and to be an excellent inhibitor of E. coli LPS-induced 
inflammatory responses both in vitro and in vivo. In study II and V, the antibody 
showed impressive inhibition of whole live E. coli bacteria-induced inflammation both 
in vitro and in vivo. Surprisingly, in study V new features of the antibody, like 
inhibition of TAT and PAI-1, markers of coagulation and fibinolysis respectively, were 
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revealed. To our knowledge, it is the first study to show that an anti-porcine CD14 
antibody inhibit LPS- and whole E. coli bacteria-induced responses in vivo. The finding 
would be useful for further studies in the pig addressing Gram-negative induced 
inflammation. 
 
CyP, a newly discovered inhibitor of TLR4/MD-2 derived from blue-green algae, 
shown to protect mice against LPS-induced shock (163), was tested in vitro in porcine 
whole blood in study III. CyP was for the first time shown to effectively inhibit E. coli 
LPS-induced production of central proinflammatory cytokines in porcine whole blood. 
However, the effect on whole E. coli bacteria-induced inflammatory response was more 
moderate.  
 
5.3 Relevance of the models- advantages and limitations 
 
5.3.1 The pig as a model animal 
 
The pig was chosen as a model animal in this Thesis. Non-human primates are probably 
the supreme model animals for studies of human diseases. Monkeys are comparable in 
nearly all physiological and immunological aspects to humans (164). It is not prohibited 
by Norwegian law to use monkeys as laboratory animals. However, ethical, animal 
fascility and economical considerations make studies on non-human primates non-
desireable and de facto impossible to conduct in Norway. Rodents like mice and rats are 
the most frequently used model animals for almost all studies of human diseases, but we 
argue that the pig has advantages over rodents in several aspects of sepsis studies. First, 
the pig is a large animal. Instrumentation, equipment like catheters, survailance, and 
intensive care treatment like volume rescucitation and medication closely resembles 
standard human critical care. Second, repeated blood sampling is not restricted in the 
same way as in smaller animals and at euthanasia tissue sampling is easy to conduct. 
Third, the anatomy and physiology of the pig closely resembles that of humans (165). 
Fourth, the pig is LPS sensitive in contrast to mice but similar to humans (166, 167), 
which is important studying Gram-negative induced inflammation. Fifth, there are high 
sequence and chromosome structure homology with humans (168), indicating that the 
majority of in particular the orthologous genes are conserved between the two species.  
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 5.3.2 Pig in vitro serum and whole blood models 
 
The in vitro serum model is a pure, but simple system. It was very useful for the 
investigation of the potential porcine complement inhibitors in study I, as these 
experiments would not be biased by other components potentially present in more 
complex experimental systems. However, serum would not be useful for the 
investigation of inflammation as such, as inflammation is an extremely complex process 
with extensive crosstalk between cascade systems and a variety of cells. In serum, most 
of these are absent, for instance the coagulation system and blood cells to mention 
some.  
 
In study II and III, a newly developed human whole blood model was tested and found 
to be feasible in pig whole blood. The model allows crosstalk between all the 
inflammatory systems in whole blood, with the exception of thrombin which is inhibited 
by the anticoagulant, lepirudin (64). The advantage of lepirudin is that it does not 
interfere with other biological systems in particular not the complement system (64), in 
contrast to other anticoagulants like EDTA, citrate and heparin (169). The whole blood 
in vitro model allowed studies on cytokine production and inhibition (study II and III), 
complement activation and inhibition (study II and III), upregulation and inhibition of a 
granulocyte marker (study II), and studies on bacterial growth and inhibition of the 
growth (study II). Although several aspects of inflammation were studied in the in vitro 
model, it has substantial inherent limitations. Important cell systems like endothel, 
which is known to be an important part of the inflammatory network in sepsis (170), 
and the solid organs are of course missing. The blood was incubated in plastic tubes, 
and was thereby in constant contact with an artificial surface during incubation. The 
plastic surface of the tubes is shown to activate the human complement system and 
complement mediated effects like upregulation of CD11b on phagocytes (171). The 
same was observed in study II, as a substantial background activation of complement 
was seen after incubation of porcine whole blood. Despite the limitations important to 
be aware of, the in vitro models used in this Thesis revealed essential information on the 
relative role of CD14 and complement in E. coli-induced inflammation and allowed 
studies of the effect of unique and rare reagents in limited amounts on this inflammatory 
response.  
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 5.3.3 Pig in vivo model 
 
As discussed in chapter 5.3.1, the pig has several advantages as a model animal. The 
pigs used in this Thesis was of outbred stock and of either sex, thus reflecting the 
diversity of sepsis patients better than inbred strains of male sex often used in rodent 
models (172). However, there are several limitations to our pig model. The pigs used in 
study IV and V were young, approximately 11 weeks old in study IV and 7 weeks old 
in study V, resembling humans in their adolescence. The pigs were healty prior to the 
experiments. In the clinical setting, patients experiencing severe infections and sepsis 
are often old and have pre-existing conditions like diabetes influencing the outcome of 
the disease. Pigs have a different RES than humans, with resident lung macrophages 
releasing mediators leading to pulmonary hypertension (141), as discussed in chapter 
3.3.2. This is not as commonly seen in human sepsis, and is important to be aware of in 
particular when interpreting physiological parameters in pig sepsis models. 
 
A limitation of both the in vitro and the in vivo models was the availability of specific 
porcine kits and reagents to detect biomarkers. We used porcine cytokine kits 
commercially available, but the numbers of such kits are limited compared to rodent and 
human kits. We used some human kits that cross-react with porcine epitopes, for 
instance the TCC ELISA (136), TAT (138), and VEGF (173). We also used kits, like 
HMGB-1, that had specificity for several species including pig and human. Kits using 
multiplex technology, which are extremely useful for detection of large numbers of 
human and mouse cytokines in small sample volumes, does not exist with pig 
specificity. Unfortunately, a human multiplex kit tested in our laboratory showed very 
little cross-reactivity with porcine cytokines (174), and could therefore not be used in 
this Thesis. 
 
5.4 Sepsis and the models 
 
An important question in all research is: Do we really study what we want to study? The 
questions may seem banal, but it is not. Projected to this Thesis the question would be: 
Did we really study sepsis? Obviously, the in vitro studies I-III was not sepsis studies 
according to the definition of sepsis outlined in chapter 1.2.1, but nevertheless brought 
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insight into aspects of the inflammatory response encountered in Gram-negative sepsis. 
The clinical course of sepsis is usually prolonged, over days to weeks. The observation 
time in our in vivo animal model was four to five hours. The observation time was 
limited by logistical challenges of these very resource-demanding experiments. We 
have therefore emphasized that early events in sepsis or septic shock are investigated in 
study IV and V. In the new pig sepsis model described in study IV, we tried two ways 
of bacterial challenge, IV or IP. The pigs challenged IV developed features of a 
systemic inflammatory response as seen in sepsis and this challenge mode was therefore 
continued in study V. IV bacterial challenge of often large doses infused over relatively 
short time is frequently used in sepsis models, but is equally frequently critizised. It is 
difficult to mimic the clinical situation with the IV challenge, as clinical sepsis develope 
slowly by intermittent release of bacteria from an infectious focus, in variable doses, 
and over an extended period of time (175). The IP challenge in study IV did not develop 
into a systemic inflammation as seen in sepsis, probably because of a 
compartmentalization of the infection and the inflammatory response to the lungs. 
Tissue compartmentalization is a well recognized feature of infections and sepsis (176). 
It is for instance shown that proinflammatory cytokines are restricted to the lung with 
unilateral pneumonia and not found in the contralateral lung (177). A systemic 
inflammatory response may occur with the compartmentilazed infection as source, but 
the limited observation time of study IV probably prevented that. IP challenge was 
therefore not conducted in study V. CLP might be the model that best mimic clinical 
sepsis (178, 179), and is frequently used in small animals. Peritonitis induced sepsis 
models are also conducted in pigs (167), and although CLP is possible to conduct and 
has been described in pig models (180), it is rarely used. A CLP model was not possible 
to use for us, because of limitations of the animal facilities and the possibilities of 
prolonged surveillance of the animals.  
 
Because of the complexity of sepsis, Marshall et al. have claimed that there is no single 
“ideal model” of sepsis or shock (181). We have developed a large animal model (study 
IV) and used it for an interventional study (study V), and despite the limitations, it has 
provided novel and important information in particular on the early phase of sepsis and 
septic shock.  
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5.5 Inflammation in sepsis and the models 
 
Sepsis is an extremely complex and heterogeneous dynamic syndrome involving most 
protein cascades, cells and organs in the body as described in chapter 1.3. Thus, 
shortcomings of in vitro and even in vivo models in sepsis studies are almost mandatory. 
An imbalance in the “inflammatory network” is depicted to be the major cause of the 
septic syndrome, an imbalance involving both exaggerated inflammation and 
immunosuppression (182). The DAMPs from either invading pathogens or damaged 
host tissue or both, initiate the inflammatory response in sepsis (7, 183). In our models 
PAMPs like LPS from E. coli and probably also alarmins from damaged tissue in the in
vivo studies contributed to the inflammatory response observed.  
 
An imbalanced cytokine response, often refered to as a “cytokine storm”, of both pro- 
and anti-inflammatory cytokines is produced in response to the initiating DAMP 
recognition (184). In the in vitro studies II and III the proinflammatory cytokines TNF-
, IL-1, and IL-8 were retrived, while IL-6 was only detected when blood was 
incubated with a high dose of LPS (study III). IL-10, VEGF, IFN-, and IL-12 were not 
detected under the conditions used in vitro. In the in vivo studies IV and V, IL-6 and IL-
10 (study IV and V) and IL-12 (study IV) and VEGF (study IV and V) were retrived in 
addition to TNF-, IL-1, and IL-8, again showing that different experimental settings 
yield different results. The cytokines are often described to have distinct time profiles in 
experimental sepsis, for instance TNF- and IL-1 are known to rise early (185), and in 
turn help induce production of other cytokines and chemokines like IL-6 and IL-8 (16). 
We showed the same cytokine pattern in study IV and V. The anti-inflammatory 
cytokine IL-10 is known be produced later in the inflammatory prosess, and high 
mobility group box-1 (HMGB-1) is another “late marker” in sepsis (186). We were not 
able to detect HMGB-1 in our in vivo model, probably because of the limited 
observation time. The anti-inflammatory cytokine IL-10, however, was detected in 
study IV and showed an interesting time course in study V discussed in chapter 5.6. As 
our models produced pro- and anti-inflammatory cytokines known to be central in the 
development of inflammation in sepsis (187), the models seem relevant for 
investigation of these aspects of inflammation.  
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As high levels of soluble TCC is shown to correlate to mortality in meningococcal 
sepsis in humans (188), we wanted to examine soluble TCC in our models. TCC was 
readily detected in vitro (study I-III), but with a distinct bacterial load-threshold of 
around 107 E. coli bacteria/ mL whole blood (study II). We were not able to detect TCC 
in vivo (study IV-V), except when a bolus of a high amount of bacteria was given to a 
pilot animal (study IV). Failure to reach a threshold of bacteria giving detectable 
soluble TCC in vivo in addition to lower sensitivity of the modified human TCC ELISA 
to porcine plasma was probably the reason for this. As wCD11R3, a phagocyte 
biomarker shown to be complement dependent in vitro (study II), was also detected in
vivo (study V), and as it is known that complement activation occur locally on the 
PAMPs on bacteria and on alarmins on damaged tissue (8), we would therefore argue 
that complement activation also took place in our in vivo model and contributed to the 
inflammatory response. 
 
Time dependent development of the dynamic sepsis syndrome, with temporal 
modulation of mediators of the inflammatory response, adds to the complexity (189). In 
this Thesis many of the central systems present in the inflammatory network was 
examined and the temporal dynamics of several mediators were shown within the limits 
of our observation times. Pro- and anti-inflammatory cytokines were shown to have 
distinct time courses (study IV-V) and these time courses differed some between the 
LPS- and E. coli challenge groups (study V). LPS is previously shown to fail to induce 
IL-1 production in vivo in humans (190), and the same was demonstrated in pigs in 
study V. Whole E. coli bacteria, on the other hand, induced substantial amounts of the 
cytokine in our in vivo model (study IV and V). The markers of coagulation (TAT) and 
fibinolysis (PAI-1) (study IV and V), the neutrophil activation marker wCD11R3 (study 
II and V), and MMP-9, an enzyme released by activated neutrophils and monocytes, 
(study IV and V) also showed time-dependency with similar trends in the LPS- and E.
coli groups.  
 
Not only are many cell and cascade systems involved in the pathogenesis of sepsis, but 
crosstalk between these systems seems to be a new emerging field in research to try to 
understand the pathogenesis (191, 192). Recent studies have revealed crosstalk between 
the complement system and TLR4. In decay accelerating factor (DAF) -/- mice, DAF is 
a membrane-bound complement inhibitor, complement via C3a and C5a were shown to 
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modulate the TLR4-induced cytokine response in vivo (193). The authors claim the 
absence of DAF may mimic overwhelming complement activation as seen in Gram-
negative sepsis, and therefore such a crosstalk may also have occurred in our models. 
Additionally, we showed that wCD11R3, a porcine analog of CD11b which together 
with CD18 forms the phagocytosis receptor CR3, was upregulated on neutrophils upon 
stimulation with E. coli in vitro and in vivo (study II and V) and LPS in vivo (study V). 
The upregulation was totally dependent on complement in vitro (study II) and partly 
dependent on CD14 in vivo (study V), demonstrating the close relationship and possible 
crosstalk between complement and CD14/TLR4. Importantly, this also indicate the 
rational for inhibition of these upstream effector systems  The possible crosstalk in these 
findings were interesting in the light of the findings by van Bruggen et al., where CR3 
was shown to be essential for uptake of the Gram-negative bacteria Salmonella enterica 
and LPS-signaling via TLR4 was essential for the subsequent killing of the bacteria via 
production of ROS by the NADPH oxidase in the phagosome (194).  
 
Coagulopathy as well as decreased fibinolysis are well known features of sepsis (195, 
196). Both of these hemostasis abnormalities, leading to the septic “procoagulant 
phenotype”, were detected in our in vivo model as both a marker for coagulation (TAT) 
and a marker for inhibition of fibrinolysis (PAI-1) increased (study IV and V). We do 
not know if the complement-coagulation crosstalk outlined in chapter 1.2.5 occurred in 
our model, but it is possible. Additionally, crosstalk between LPS activated platelets 
through TLR4 and neutrophils are described (197). The binding of these platelets to 
neutrophils leads to neutrophil activation and degranulation, demonstrated among other 
things by MMP-9 release. DNA is also released and subsequent formation of DNA-
composed extracellular traps to ensnare bacteria in septic blood occurs. In study IV and 
V we demonstrated MMP-9 release in our in vivo model and that the release was 
partially CD14 dependent (study V). This dependency might reflect such a 
CD14/TLR4-mediated platelet-induced neutrophil activation. 
 
In summary, the models in this Thesis revealed several central biomarkers of 
inflammation and their relative dependency on complement and CD14, as well as their 
relative time-dependency in vivo. The studies also exhibited crosstalk in the 
inflammatory network as seen in human clinical sepsis. Put together, the findings 
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enlightened important aspects of inflammation and showed that our models were 
relevant for studies of inflammation in sepsis. 
  
5.6 New treatments in sepsis and possible clinical application of the 
results
 
Single downstream mediator neutralization to dampen inflammation, like TNF- or IL-
1 inhibition, have failed as a treatment strategy in sepsis (198). The same is the case 
for neutralization of LPS of Gram-negative bacteria (199). Regarding LPS inhibition, 
the principal differences between LPS and whole Gram-negative bacteria may explain 
some of the failure to translate promising preclinical endotoxin studies to clinical trials 
(200). In general, factors like heterogenous patient populations in age, inclusion time 
and severity of sepsis, have obviously contributed the treatment-trial failures (100, 201). 
The many disappointments of anti-inflammatory therapies in sepsis have led some 
researchers to ask the question if mortality in sepsis is not derived from an uncontrolled 
proinflammatory response (202). However, the complex interplay between the many 
pathogenic mediators, probably impossible to dampen with single target approaches, 
might be the main reason for the failures (198, 203).  
 
Despite the complexity of sepsis and the vast amount of biomarkers, including 
cytokines, complement- and coagulation activation products, enzymes, ROS etc. 
correlated with development, severity or mortality of the syndrome, the expression of 
all these mediators is regulated through a relative small number of signalling pathways 
(204). Targeting upstream PRRs seems to be a better approach than single mediators of 
the septic inflammation. These central effector-pathways, which recognizes DAMPs  
(PAMPs and alarmins), initiates inflammation (14, 65, 205). Inhibing the upstream 
inducers instead of the downstream mediators of inflammation in sepsis, is an 
alternative treatment regimen (28, 151, 204, 206). Inhibition of two of these central 
upstream inducers of inflammation, complement and CD14/TLR4, was examined in this 
Thesis. We found that the inhibition led to reduction of a range of proinflammatory 
cytokines in vitro (study II and III) and in vivo (study V). The anti-inflammatory 
cytokine IL-10 clearly differed from the proinflammatory cytokines in vivo. In the E.
coli-arm in study V the increase was delayed, but reached levels higher than in the 
positive control group. This could be beneficial in sepsis as IL-10 dampens the 
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inflammatory response and may enhance the effect of antibiotics (207). Activation of 
hemostasis (study V) and granulocytes (study II and V) was also inhibited in vitro and 
in vivo by targeting these two upstream danger sensor systems. Not only changes 
induced by LPS, but also largely those induced by whole live E. coli bacteria were 
inhibited.  
 
There is a concensus in the scientific community that systemic inflammation induced by 
the host’s response to DAMPs, PAMPs on invading pathogens and alarmins on 
damaged tissue are harmful and contribute to the development of severe sepsis and 
septic shock (202). The findings in this Thesis suggest that inhibition of 
CD14/TLR4/MD-2 and complement should be regarded as an early treatment approach 
in sepsis.   
 
5.7 Future perspectives 
 
The hypothesis of upstream inhibition of complement to dampen parts of the Gram-
negative bacteria-induced inflammation has been demonstrated in vitro (study I and II). 
Inhibition of another upstream danger sensor, the TLR4/CD14/MD-2 complex, by anti-
CD14 (study II), or an inhibitor of MD-2/TLR4, CyP (study III), showed additional 
anti-inflammatory effects to complement inhibition in vitro. The anti-inflammatory 
effect of anti-CD14 was confirmed and extended in vivo (study V).  
The potent inhibitory response of CyP on LPS- but not E. coli-induced inflammatory 
response would be interesting to investigate further, and a study of the effects of two 
different fractions of CyP on this response is on its way. A continuation of the anti-
CD14 study in vivo would be to look at inflammatory biomarkers including gene-
regulation in the tissues and compare them with the results in blood obtained in study V. 
This could point to the relative role of the solid organs in relation to the blood in 
systemic inflammation, and reveal if anti-CD14 has any inhibitory effect on 
inflammation in the tissues. If so, tissue targeting of anti-CD14 could be a treatment 
approach. As complement inhibitors and anti-CD14 were shown to have complementary 
and differential inhibitory effects in vitro in pigs, and as a pronounced inhibitory 
synergism is previously shown in vitro in humans (64, 139, 171), it would be extremely 
interesting to investigate a combination of a complement inhibitor and anti-CD14 or 
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CyP, in vivo in our pig model. Unfortunately, an available large scale produced specific 
complement inhibitor working in pigs has been impossible to provide up till now. 
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6 Conclusions 
1. The Orthopox-viral complement control proteins VCP and SPICE were shown to be 
excellent inhibitors of complement in porcine serum and whole blood in vitro. The 
proteins also inhibited upregulation of wCD11R3 (part of the phagocytosis-receptor 
CR3) and production of the chemokine IL-8 in whole blood, and thereby showed that 
these two biomarkers were complement dependent. 
 
2. The complement inhibitor SPICE was shown to inhibit clearance of E. coli in porcine 
whole blood in vitro, thereby showing that the clearance is partly complement-
dependent. The anti porcine-CD14 antibody did not influence clereance of E. coli either 
in vitro or in vivo in the pig, showing that the LPS-receptor is not responsible for 
bacterial clearance. 
 
3. Inhibition of the CD14/TLR4/MD-2 LPS-receptor complex by either anti-CD14 or 
CyP was shown to be an efficient way to reduce production of the E. coli LPS-induced 
proinflammatory cytokines TNF-, IL-1 and IL-8 in vitro. Anti-CD14 was also shown 
to inhibit E. coli LPS-induced TNF-, IL-6 and IL-8 production in vivo in pigs. 
 
4. Inhibition of CD14 reduced whole live E. coli bacteria-induced production of TNF- 
and IL-1 in vitro and in vivo in the pig, and IL-6 in vivo, while production of IL-8 was 
inhibited in vivo but not in vitro.  
 
5. Inhibition of CD14 reduced E. coli-induced upregulation of wCD11R3 in vivo, but 
not in vitro. Both TAT and PAI-1 and thereby the procoagulant state seen in sepsis was 
inhibited in vivo by anti-CD14. 
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In summary, complement and CD14 were shown to be important upstream danger 
sensing molecules mediating the host’s inflammatory response to the Gram-negative 
bacteria E. coli in vitro and anti-CD14 showed an impressive inhibition of a broad 
spectrum of inflammatory mediators in vivo in a pig model. Important differences in the 
inflammatory response between challenge with E. coli LPS and whole live E. coli 
bacteria and between the in vitro and the in vivo system, were revealed. This emphasizes 
the importance of carefull interpretation of the model used in respect to the potential 
effect in a human clinical setting. Inhibition of complement and CD14 are promising 
therapeutic targets to dampen the overwhelming inflammatory response seen in sepsis, 
and may be useful in a clinical setting in the future. 
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